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AdnectinsTM are a new family of therapeutic proteins
based on the 10th ﬁbronectin type III domain, and
designed to bind with high afﬁnity and speciﬁcity to
therapeutically relevant targets. Adnectins share with
antibody variable domains a beta-sheet sandwich fold
with diversiﬁed loops, but differ from antibodies in
primary sequence and have a simpler, single-domain
structure without disulﬁde bonds. As a consequence,
Adnectins bind targets with afﬁnity and speciﬁcity as
high as those of antibodies, but are easier to manipulate
genetically and compatible with bacterial expression
systems. Adnectins that bind macromolecular targets with
nanomolar and picomolar afﬁnity have been selected
using in vitro evolution methods, including mRNA
display, phage display and yeast display. CT-322, a
PEGylated, anti-angiogenic Adnectin that binds vascular
endothelial growth factor (VEGF) receptor 2 and blocks
its interaction with VEGF A, C and D, is being evaluated
in Phase II clinical trials for efﬁcacy in several oncology
indications.
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Antibodies and designed target-binding proteins
Over the past 20 years, antibodies that bind therapeutically
relevant targets have become the fastest growing class of
protein drugs, with 30 approved therapeutic antibodies on
the market and 200 currently in clinical trials (Beck et al.,
2010). Two of the reasons for this success are the high afﬁ-
nity and exquisite speciﬁcity of antibodies, which allow
therapy to be targeted to speciﬁc cells or signaling pathways.
In addition, since adaptive antibodies are part of the natural
human response to infection, antibody drugs of mostly
human molecular origin tend to have relatively low immuno-
genicity, a long half-life in the bloodstream and low toxicity
due to limited off-target effects.
Discovery of therapeutic antibodies is a lengthy and
complex process. The traditional hybridoma technology
(Kohler and Milstein, 1975) consists of evoking a rodent
immune response against the antigen of interest; screening
myeloma-fused B-cells to identify those producing functional
antibodies; and replacing the majority of the active rodent
antibody sequence with analogous human sequence, preser-
ving only the residues involved in target binding (humaniza-
tion). Humanization is not required when the immunized
rodents are transgenic and carry genetic material that
encodes a human antibody repertoire (Lonberg, 2008). The
most common alternative process, in vitro evolution, starts
with construction of a library of antibody fragments, which
can be obtained by capturing the natural diversity of anti-
body variable domains from human donors, by diversifying
their sequences synthetically, or by combining the two
approaches. The resulting library is then used to select the
combination of variable heavy and light chains that bind the
target antigen, using a display technology such as phage
display (Bradbury and Marks, 2004; Thie et al., 2008), yeast
display (Chao et al., 2006), mRNA display or ribosome
display (Lipovsek and Pluckthun, 2004; Groves and Osbourn,
2005). Finally, the selected variable domains are reformatted
into full-length antibodies. Engineered full-length mono-
clonal antibodies identiﬁed by either hybridoma technology
or by in vitro evolution contain both variable domains that
mediate target recognition and constant domains that mediate
effector function such as recruitment of other components of
the immune system. Almost invariably, engineered full-
length antibodies are produced in mammalian cell culture.
The success of therapeutic monoclonal antibodies has
sparked a growing interest in creating streamlined molecules
that retain the tight and speciﬁc target binding, low toxicity
and low immunogenicity of antibodies, but are faster to dis-
cover as well as easier and less expensive to manufacture. In
addition, there is an interest in developing smaller target-
binding proteins that may penetrate tissues faster, and that
lack the Fc-mediated effector function, which is unnecessary
in a simple antagonist of receptor–ligand interactions or in a
delivery vehicle for a toxic payload. The ﬁnal objective for
the next generation of target-binding therapeutic proteins is
modularity: the ability for proteins with different binding
speciﬁcities to be genetically linked in order to generate bi-
or multi-speciﬁc molecules, an engineering task that is chal-
lenging for traditional, full-length antibodies.
These considerations ﬁrst led to the development of small
engineered antibody fragments, including single-chain anti-
bodies (Huston et al., 1991), which comprise two genetically
fused antibody variable domains, one from the heavy chain
and one from the light chain; and domain antibodies (Holt
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contain a single variable domain of human or humanized
camelid origin, respectively (Fig. 1a).
In an even further departure from natural antibodies, the
drive for simplicity, modularity, ease of production and
favorable biophysical properties has led to the invention of
designed target-binding proteins, also known as engineered
scaffolds and antibody mimics (Binz and Pluckthun, 2005;
Gebauer and Skerra, 2009). Designed binding proteins are
relatively small, single-chain and single-domain proteins
with engineered sequence diversity that allows high-afﬁnity,
speciﬁc binding to a wide range of target antigens. They are
highly stable, soluble and well expressed in microbial
systems. They can be selected from in vitro-generated
libraries in their ﬁnal therapeutic format, ensuring a fast dis-
covery process, and they can be linked to create multi-
speciﬁc therapeutics. Owing to their small size, most thera-
peutic designed target-binding proteins need to be modiﬁed
to avoid fast renal clearance. Popular examples of this
approach are chemical modiﬁcation such as PEGylation and
genetic linkage to a protein domain that binds a component
of plasma, such as human serum albumin (Holt et al., 2008).
Adnectins, a family of designed proteins based on the fra-
mework of the 10th human ﬁbronectin type III domain
(
10Fn3; Fig. 1b and c), are among the earliest advanced
designed binding proteins, and have progressed the furthest
in clinical studies.
10Fn3 as the starting point for Adnectin design
The 10th ﬁbronectin type III domain was utilized as the start-
ing point for the design of a family of target-binding proteins
due to its structural similarity to antibody variable domains,
suitability for modular assembly into multi-functional mol-
ecules, favorable biophysical properties and its abundance in
human blood and extracellular matrix, which demonstrates
that inherently this scaffold is not toxic or immunogenic.
Despite the lack of signiﬁcant sequence homology, anti-
body variable domains and
10Fn3 (Main et al., 1992;
Dickinson et al., 1994) have similar structures. As is illus-
trated in Fig. 1c, both antibody variable domains and
10Fn3
are sandwiches of two anti-parallel beta sheets, with
solvent-accessible loops at each pole of the domain. One
structural difference between the two is that, whereas the two
beta sheets in antibody domains are linked through a disul-
ﬁde bridge,
10Fn3 contains no disulﬁdes or free cysteines
(Fig. 1C). As a consequence,
10Fn3 retains its high thermo-
stability [as manifested in a melting temperature above 808C
and free energy of unfolding between 6 and 9 kcal/mol
(Plaxco et al., 1997; Cota et al., 2000; Batori et al., 2002)]
under reducing conditions, and can be produced with a high
yield in bacteria. Another difference is that antibody variable
domains are somewhat larger than
10Fn3, with two more beta
strands and an extra turn, which is not typically involved in
antigen binding.
Loops BC, DE and FG of
10Fn3 are structurally analogous
to the antibody complementarity-determining regions (CDR)
H1, H2 and H3, respectively, and are thus the obvious candi-
dates for diversiﬁcation to generate artiﬁcial target-binding
surfaces. The three loops at the opposite pole of
10Fn3, AB,
CD and EF, are also candidates for diversiﬁcation (Koide
et al., 2002; Bloom and Calabro, 2009). Sequence alignment
of
10Fn3 to other ﬁbronectin type III domains reveals a diver-
gence in loop sequence and length (Dickinson et al., 1994),
suggesting that the
10Fn3 fold is likely to be compatible with
artiﬁcial diversiﬁcation of the six loops. The tolerance of ﬁve
of the six
10Fn3 loops, AB, BC, CD, DE and FG, to
re-engineering has been conﬁrmed by the stability of
10Fn3
mutants following insertion of four glycines into these loops
(Batori et al., 2002) or following random mutagenesis of BC
and FG loops (Olson and Roberts, 2007). Even more relevant
is the ability of several different groups to select and engin-
eer
10Fn3-derived Adnectins with mutated BC, DE and FG
loops, and, in one case, with mutated AB loop (Table I)
(Koide et al., 1998, 2002, 2007; Xu et al., 2002; Richards
et al., 2003; Karatan et al., 2004; Parker et al., 2005;
Getmanova et al., 2006; Lipovsek et al., 2007; Gilbreth
et al., 2008; Hackel et al., 2008; Olson et al., 2008; Liao
et al., 2009; Hackel and Wittrup, 2010; Hackel et al., 2010;
Wojcik et al., 2010). Whereas thermostability and solubility
of
10Fn3 can decrease once its loops are replaced to allow
Fig. 1. Engineered antibodies and
10Fn3-based target-binding proteins in
context. (A) Comparison of three-dimensional structures of a full-length
monoclonal, IgG, antibody (PDB ID: 1ITGY; Harris et al., 1998),
single-chain antibody (scFv) and domain antibody (VH; shown in teal).
Complementarity-determining regions of the heavy-chain variable domains
are shown in blue (CDR-H1), green (CDR-H2) and red (CDR-H3). (B)
Comparison of three-dimensional structures of a fragment of human
ﬁbronectin (type III domains 7210) (PDB ID: 1FNF; Leahy et al., 1996)
and of a single 10th ﬁbronectin type III domain (
10Fn3; shown in orange).
The three loops analogous to CDRs typically diversiﬁed in
10Fn3-based
libraries are shown in blue (BC), green (DE) and red (FG). (C) Detailed
comparison of three-dimensional structures of VH and of
10Fn3, showing
diversiﬁed loops [colored as in (a) and (b)] and the disulﬁde bond in the VH
domain (black).
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4Table I. Published selections of
10Fn3-based target-binding proteins (in chronological order of publication)
Reference Target Display
method
Size
of
naı ¨ve
library
Diversi-ﬁcation
method
AB
a BC
a DE
a FG
a Aff.
mat.
b
Scaff.
mut.
c
Lowest
Kd (M)
d
Tm
(8C)
e
Comments
Koide et al.
(1998)
Ubiquitin Phage
display
10
8 NNK
f — AVTVR
X5
GRGDSPAS
X5
No No 10
26
(IC50)
ND
g
Koide et al.
(2002)
Estrogen
receptor
a-ligand
Yeast
two-hybrid
10
6 NNK/NNS
f — — — RGDSPAS
X7
No No ND ND Conformation-speciﬁc,
binds receptor in yeast
cells
Koide et al.
(2002)
Estrogen
receptor a
ligand
Yeast
two-hybrid
10
5 NNK/NNS
f TPTS
TPX7TS
— — — No No ND ND Fewer solutions than for
FG-based library; not
conformation-speciﬁc
Xu et al.
(2002)
TNF-a mRNA
display
10
12 NNS
f — DAPAVTV
X7
GSKS
X4
GRGDSPASSK
X10
Yes Multiple 10
211 ND Spontaneous deletions in
loops favored
Richards
et al. (2003)
avb3 integrin Phage
display
10
9 NNK
f — — — GRGDSPAS
XRGDXXXX
No No 10
29
(IC50)
ND Inhibit avb3-cell
binding
Karatan
et al. (2004)
Src SH3 Phage
display
10
9 NNK
f — AVTVR
X5
— GRGDSPAS
X5
No Yes 10
27 ND Detect western blots
Getmanova
et al. (2006)
VEGF-R2 mRNA
display
10
13 NNS
f — DAPAVTV
X7
GSKS
X4
GRGDSPASSK
X10
Yes Rare 10
210 32–
62
h
VEGF antagonists;
cell-based
IC50¼ 10
29 M
Lipovsek
et al. (2007)
Lysozyme Yeast
display
10
8 20-codon mix — DAPAVTV
X7
— GRGDSPA
X7
Yes Rare 10
210 ND Likely BC-FG disulﬁde
Koide et al.
(2007)
MBP,
hSUMO4,
ySUMO
Phage,
yeast
display
10
10 Tyr/Ser (TMT) — PAVTVR
(Y/S)4–8VS
GSKS
(G/Y/S)(Y/S)3–7
VTGRGDSPA
(Y/S)9–13
No D3S,
D7K
10
28 ND Crystal structure of
MBP-Fn fusion
Hackel
et al. (2008)
Lysozyme Yeast
display
10
7 NNB
f — DAPAVTVR
X6–9
GSKST
X4–7
GRGDSPASSK
X5,6,8,10
Yes Multiple 10
212 51–
60
Extensive afﬁnity
maturation
Olson et al.
(2008)
Phospho-IkBa mRNA
display
10
13 NNS
f — DAPAVTV
X7
— GRGDSPASSK
X10
No 4(127)
i
Yes
10
28 ND Optimized for solubility;
phospho-speciﬁc
Liao et al.
(2009)
SARS N
protein
mRNA
display
10
12 NNS
f — DAPAVTV
X7
— GRGDSPASSK
X10
No 4(127)
Yes
10
29 ND Inhibit viral replication
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5Table I. Continued
Reference Target Display
method
Size
of
naı ¨ve
library
Diversi-ﬁcation
method
AB
a BC
a DE
a FG
a Aff.
mat.
b
Scaff.
mut.
c
Lowest
Kd (M)
d
Tm
(8C)
e
Comments
Gilbreth
et al. (2008)
MBP Phage,
yeast
display
10
10 9-codon mix
biased towards
Tyr, Ser, Gly
— PAVTVR
X4–8VS
GSKS
X4–8
VTGRGDSPA
X9–13
No D3S,
D7K
10
28 ND Higher afﬁnity than in
MBP binders using
binary Y/S diversity.
Crystal structures.
Hackel and
Wittrup
(2010)
IgG Yeast
display
10
8 NNB (X);
Tyr/Ser
— DAPAVTVRY
X6–9Y
(Y/S)7–10
GSKST
X4–7
gsX0,1,3st
j
GRGDSPASSK
X5,6,8,10
(Y/S)6,7,8,10
Yes Multiple 10
210
(NNB)
10
28
(S/Y)
45–
64
NNB diversity and
wt-or-shorter loops
favored
Wojcik
et al. (2010)
Abl SH2 Phage
display
10
10 19-codon mix
biased toward
Tyr, Ser, Gly
— PAVTVR
X4–8VX
GSKS
(G/Y/S)(Y/S)3
VTGRGDSPASSK
X7–13
Yes D3S,
D7K
10
28 ND Inhibits Abl
autophosphorylation
and signaling. Crystal
structure
Hackel
et al. (2010)
EGFR, A33,
HSA, FcgIIa,
FcgIIIa, IgG
Yeast
display
10
8 NNB, Tyr/Ser,
‘G4’
k
— DAPAVTVRY
X7–10
GSKST
gsX0,1,3st
j
GRGDSPASSK
X5,6,8,10
Yes Multiple 10
210 53–
73
‘G4’ library
outperformed NNB and
Y/S
aAB, BC, DE, FG:
10Fn3 loops diversiﬁed to make the original, naı ¨ve library. The peptide sequence shown in the top line marks the wild-type
10Fn3 positions replaced by a mixture of residues; the second line
deﬁnes the nature of diversiﬁcation.
bAfﬁnity maturation used—i.e. populations or individual clones selected from the naı ¨ve library were re-diversiﬁed and subjected to another selection to yield variants with even
higher afﬁnity for the target.
cScaff. mut.: Scaffold mutations, i.e. mutations outside the intentionally diversiﬁed loops, were found in selected variants.
dLowest Kd: Dissociation constant of the highest-afﬁnity
variant found in the selection.
eTm, melting temperatures of selected variants.
fNNK, NNS, NNB: Diversiﬁed codons commonly used to encode any natural amino-acid residue. In all cases, the ﬁrst and the second
position in the codon are synthesized using the ‘N’ phosphoramidite mix, which is an equimolar mixture of all four nucleotides (A, G, C and T). The third position is synthesized using mix ‘K’ (G or T), ‘S’ (G or
C) or B (C, G or T).
gND, not determined.
hParker et al. (2005).
i4(127): The seven N-terminal residues were deleted during library construction.
jg, s, t: 50% the wt G, S or T, 50% any other amino-acid residue;
encoded at nucleotide level.
k‘G4’: complex diversity scheme encoded by nucleotide mixes and designed (i) to approximate amino-acid distribution in antibody CDR-H3 and (ii) for higher probability of wild-type
residues in positions deemed important for domain stability.
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6target binding, the extremely high stability of the wild type
means that even destabilized variants can be sufﬁciently
stable for therapeutic applications (Parker et al., 2005;
Hackel et al., 2008, 2010; Hackel and Wittrup, 2010). In
addition, several studies have demonstrated the utility of
approaches based on in vitro selection and on directed engin-
eering that can increase the stability of wild-type
10Fn3 and
its target-binding mutants (Koide et al., 2001; Dutta et al.,
2005; Olson et al., 2008).
Another advantage of
10Fn3-based target-binding proteins
is that they are naturally well suited for multimerization to
generate multi-functional binding molecules. In nature,
10Fn3
is a component of ﬁbronectin, a long, single-chain polypep-
tide comprised type I, II and III domains separated by short
linkers, with limited interactions between adjacent domains
(Fig. 1b). A genetically linked string of Adnectins with
different speciﬁcities closely mimics this natural arrangement
and is thus likely to be compatible with independent folding,
stability and function of the individual binding domains. In
contrast, antibody variable domains are parts of a more
compact, three-dimensional structure, with extensive packing
and functional inter-dependence between the variable light
and heavy domains (Fig. 1a).
The functional role of
10Fn3 in human ﬁbronectin, integrin
binding, is mediated by the RGD tripeptide found in the FG
loop (Leahy et al., 1996); once that sequence is changed by
site-directed mutagenesis or library diversiﬁcation,
10Fn3 is
stripped of its natural physiological function, and thus
is expected to behave as an inert, non-toxic and non-
immunogenic carrier of engineered, target-binding loops.
The process of Adnectin discovery
The steps that lead from human
10Fn3 to therapeutic
Adnectins include:
(i) design and construction of
10Fn3-based libraries
(Xu et al., 2002);
(ii) selection of target-binding molecules from the library
using in vitro display (Xu et al., 2002; Getmanova
et al., 2006);
(iii) screening of selected sequences for predicted immuno-
genicity (De Groot et al., 2008);
(iv) screening of individual selected, bacterially produced
proteins for favorable biophysical properties, including
detailed binding kinetics, epitope-mapping, stability
and solubility;
(v) screening of the proteins for in vitro activity in cell-
based assays;
(vi) optimization of selected Adnectins by focused
re-diversiﬁcation and re-selection (Xu et al., 2002;
Getmanova et al., 2006);
(vii) modiﬁcation for improved pharmacokinetics;
(viii) characterization of biological efﬁcacy in animal
models (Dineen et al., 2008; Mamluk et al., 2010);
(ix) clinical trials in human patients (Tolcher et al., 2010).
In addition, detailed structural characterization of
Adnectin-target complexes using X-ray crystallography con-
tinues to inform the discovery process, especially library
design and optimization strategies.
The two earliest
10Fn3-based library designs, published by
Koide et al. (Koide et al., 1998) and Xu et al.( Xu et al.,
2002), were guided primarily by structural and sequence
alignments between
10Fn3, antibody variable domains and
other Fn3 domains. The Koide library diversiﬁed ﬁve resi-
dues in the BC loop and ﬁve residues in a shortened FG
loop, whereas the Xu library diversiﬁed seven residues in the
BC loop, four residues in the DE loop and 10 residues in the
full-length FG loop. In both cases, the diversiﬁed residues
were encoded by a mixture of nucleotides that allowed any
amino-acid residue to appear in any diversiﬁed position, with
different amino acids represented at different frequencies due
to the uneven redundancy of the genetic code. Koide et al
used phage display to select proteins that bound ubiquitin
with low-micromolar afﬁnity, whereas Xu et al used mRNA
display (PROfusionTM) to select Adnectins that bound
TNF-alpha with low-nanomolar afﬁnity (after primary selec-
tion) and sub-nanomolar afﬁnity (after afﬁnity maturation).
The library described by Xu et al became the ﬁrst source of
therapeutic Adnectins for Adnexus (now a Bristol-Myers
Squibb R&D company); the selection from a larger library
of the same design for binding to vascular endothelial
growth factor receptor 2 (VEGF-R2) gave rise to CT-322,
the Adnectin currently in clinical trials against glioblastoma
multiforme, non-small cell lung cancer and metastatic color-
ectal cancer (Getmanova et al., 2006; Dineen et al., 2008;
Mamluk et al., 2010).
Since the publication of the ﬁrst
10Fn3-based libraries,
library design has increased in complexity and sophistication,
both in the choice of residues to diversify and in the ratio of
amino-acid residues allowed in each diversiﬁed position.
Several groups have published a variety of successful combi-
nations of
10Fn3-base libraries and display methods
(Table I). Target-binding molecules with low nanomolar to
picomolar afﬁnity have been selected from libraries of
between 10
7 and 10
13 different variants generated by the
diversiﬁcation of the three CDR-like loops of human
10Fn3,
BC, DE and FG, using phage, yeast or mRNA display.
In several of the studies, diversity in the loop length as
well as in loop sequence appeared to have contributed to
high afﬁnity of selected variants (Xu et al., 2002; Koide
et al., 2007; Hackel et al., 2008, 2010; Hackel and Wittrup,
2010; Wojcik et al., 2010), and two studies identiﬁed selected
pairs of cysteines predicted to be sufﬁciently close in space
to form interloop disulﬁde bonds (Lipovsek et al., 2007;
Hackel et al., 2010).
The published crystal structures of maltose-binding protein
in complex with cognate
10Fn3 variants (Koide et al., 2007;
Gilbreth et al., 2008) conﬁrmed the pivotal role of tyrosines
at the
10Fn3-antigen interface, at least where the diversiﬁed
loop positions in the library were rich in tyrosine and serine,
in agreement with the effect seen earlier in engineered anti-
bodies (Fellouse et al., 2004, 2005). Still, when outcomes
from similar selections were compared, libraries with a
broader side-chain diversity appeared to have an advantage.
In two separate selections from libraries of similar design, a
library that allowed nine different amino-acid residues but
favored tyrosine, serine and glycine (Gilbreth et al., 2008)
yielded variants with higher afﬁnity than did a binary tyro-
sine/serine library (Koide et al., 2007). Similarly, when two
libraries with different diversity distributions were mixed and
selected from simultaneously, the library that allowed the
Adnectins: engineered therapeutic proteins
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yielded target-binding variants with higher afﬁnity than did
the library with diversity restricted to a tyrosine and serine
(Hackel and Wittrup, 2010). A further study added a third,
more complex library to the mix: diversity distribution in
this third library both attempted to mimic the distribution of
amino-acid residues in antibody CDR-H3 (with particularly
high proportion of tyrosine (18%), serine, glycine, aspartic
acid and arginine), and took into account the degree of pre-
ference for wild-type residues at each positions in the three
10Fn3, CDR-like loops (Hackel et al., 2010). This complex
library, named ‘G4’, yielded about 90% of the target-binding
variants against several different targets, with the remaining
10% of the variants originating from the fully diversiﬁed
library using a random nucleotide mix, and none of the var-
iants originating from the library with diversity restricted to
a tyrosine and serine. These studies suggest that, whereas a
high proportion of tyrosine in diversiﬁed loops is beneﬁcial
to binding, further beneﬁt can be derived from the avail-
ability of a broad range of functional side chains.
Adnectins in the clinic
Of the properties critical for development of Adnectins as
therapeutics, their ability to bind a wide range of targets is
the best documented (Table I). Afﬁnities as high as 1 pM
have been reported (Hackel et al., 2008), with numerous
examples of Adnectins that bind targets in the sub- to low
nanomolar range (Table I). This afﬁnity range is comparable
to that of therapeutic antibodies, and sufﬁcient to target cells
overexpressing the antigen and to inhibit many therapeuti-
cally relevant interactions. Several of the studies also report
Adnectin binding or biological activity in cell-based assays
(Richards et al., 2003; Getmanova et al., 2006; Wojcik et al.,
2010) or high thermostability (Parker et al., 2005; Hackel
et al., 2008, 2010; Hackel and Wittrup, 2010), both essential
properties of a therapeutic-protein lead.
In our experience, high afﬁnity for an appropriately for-
matted and biologically active target often translates into
high activity in cell-based assays and into efﬁcacy in animal
studies. For example, the PEGylated Adnectin CT-322,
which has a dissociation constant from VEGF-R2 of 11 nM,
inhibits VEGF-dependent proliferation of VEGF-R2 expres-
sing cell lines and of human umbilical vein endothelial cells
(Mamluk et al., 2010), and shows efﬁcacy against xeno-
graphs in mice (Dineen et al., 2008; Mamluk et al., 2010). In
Phase I clinical trials (Sweeney et al., 2008; Tolcher et al.,
2010), CT-322 had an 100 h half-life in the bloodstream,
was well tolerated, did not give rise to neutralizing anti-
bodies and did not show signs of antibody-mediated clear-
ance. In addition, administration of CT-322 altered
physiological markers associated with VEGF-R2-dependent
signaling, including elevating blood pressure and VEGF-A
levels, indicating that the drug was biologically active in
humans. Phase II trials are underway to evaluate the efﬁcacy
of CT-322, in combination with chemotherapy or with che-
motherapy and radiation, against glioblastoma multiforme,
non-small cell lung cancer and metastatic colorectal cancer
(www.clinicaltrials.gov).
Future directions
CT-322 is only the ﬁrst therapeutic Adnectin to emerge from
a large series of Adnexus (Bristol-Myers Squibb) programs
against therapeutic targets. Advanced library design and
screening methods continue to generate high-potency
Adnectins with excellent biophysical properties.
Single-domain Adnectins like CT-322 are being followed by
multi-domain Adnectins, with each domain contributing
binding speciﬁcity for a different target. One such tandem
Adnectin lead consists of an N-terminal Adnectin that binds
epidermal growth factor receptor with 0.7 nM afﬁnity and a
C-terminal Adnectin that binds insulin-like growth factor 1
receptor with 0.1 nM afﬁnity (Emanuel et al., 2010), leading
to anti-proliferative effects through two separate pathways.
Modularity of Adnectins is also being used to develop an all-
protein therapeutic where improvement in pharmacokinetic
properties is mediated by an Adnectin domain binding to
human serum albumin instead of by chemical modiﬁcation.
In the longer term, the combination of modularity, small size
and high stability of Adnectins also makes them excellent
candidates for development of sustained-release products and
other delivery alternatives to injection.
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